louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03119506: Effects of Recess Timing and Activity on Children's Eating Behaviors
Official title: Effects of Recess Timing and Activity on Children's Eating Behaviors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Activity
Diet Habit
Health Behavior
Lead sponsor: University of Illinois at Urbana-Champaign
Sponsor class: OTHER
First posted: 2017-04-18
Enrollment: 151
Sex: ALL
Minimum age (years): 8
Maximum age (years): 11
Standard ages: CHILD
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elementary School Children

Brief summary: This study aims to understand the interaction between school recess activity and duration and lunch choices among elementary school children


Eligibility criteria: Inclusion Criteria:

* Parental/guardian consent
* 8-11 years of age

Exclusion Criteria:

* No parental/guardian consent
* Below 8 years and above 11 years

Primary outcomes:
measure: Objectively Measured Physical Activity during Recess
timeFrame: Immediately following or before lunch
Secondary outcomes:
measure: Executive Function
timeFrame: Measured within 1 week of Physical Activity Assessment
measure: Weight Status
timeFrame: Measured within 1 week of Physical Activity Assessment
measure: Plate Waste at Lunch
timeFrame: Immediately following or before recess
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04224506: A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Official title: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Myasthenia Gravis
Myasthenia Gravis, Generalized
Lead sponsor: ProgenaBiome
Sponsor class: OTHER
First posted: 2020-01-13
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Myasthenia Gravis

Brief summary: This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed description: The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to Myasthenia Gravis.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

   a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent
2. Male or female of all ages.
3. Diagnosis of Myasthenia Gravis by a physician

Exclusion Criteria:

1. Refusal to sign informed consent form
2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
3. Postoperative stoma, ostomy, or ileoanal pouch
4. Participation in any experimental drug protocol within the past 12 weeks
5. Treatment with total parenteral nutrition

Primary outcomes:
measure: Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing
timeFrame: Three years
Secondary outcomes:
Other outcomes:
Locations:
city: Ventura
country: United States
facility: ProgenaBiome
state: California
Study officials:
affiliation: ProgenaBiome
name: Sabine Hazan
role: STUDY_DIRECTOR
References:
Clinical trial NCT05499299: Volatility and Heterogeneity of Vaccine Sentiments Means Continuous Monitoring is Needed When Measuring Message Effectiveness
Official title: The Effect of Optimised Online Advertising on the Uptake of COVID-19 Vaccines in Hong Kong
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaccine-Preventable Diseases
Vaccine Refusal
Keywords: Vaccine hesitancy
Google ads
Vaccine messages
Vaccine confidence
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2022-08-12
Enrollment: 127000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The success of vaccination programs often depends on the effectiveness of the vaccine messages, particularly during emergencies such as the COVID-19 pandemic. The current suboptimal uptake of COVID-19 vaccines across many parts of the world highlights the tremendous challenges in overcoming vaccine hesitancy and refusal even in the context of a world-devastating pandemic. The investigators conducted a randomized controlled trial in Hong Kong to evaluate the impact of seven vaccine messages on COVID-19 vaccine uptake (with the government slogan as the control). The participants included 127,000 individuals who googled COVID-19-related information during July-October 2021.

Detailed description: This study aims to evaluate the effectiveness of using the Google advertising platforms on influencing the uptake of COVID-19 vaccines in Hong Kong. When completed, the rich database compiled through this proposed study will provide increased insight into vaccine hesitancy in Hong Kong. Insights from the optimised online advertising trial can aid in providing crucial technical and theoretical support to the relevant health authorities for any potential evidence-based policy intervention in addressing vaccine hesitancy issues or the public's concerns towards vaccines in Hong Kong.

Eligibility criteria: Inclusion Criteria:

* General users of Google search in Hong Kong

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of bookings following each message delivery within 6 hours
timeFrame: 6 hours
Secondary outcomes:
measure: Number of bookings following each message delivery within 3 hours
timeFrame: 3 hours
measure: Number of bookings following each message delivery within 12 hours
timeFrame: 12 hours
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The University of Hong Kong
Study officials:
affiliation: The University of Hong Kong
name: Joseph T Wu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01972399: Laser Therapy Treatment of Peri-implantitis.
Official title: Influence of Laser Therapy Upon Surgical Treatment of Peri-implantitis Lesions.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Peri-implantitis
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-10-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to compare the clinical outcomes of using Er: YAG laser along with bone graft and barrier membrane to conventional mechanical debridement also with bone graft and barrier membrane in the treatment of peri-implantitis infections.


Eligibility criteria: Inclusion Criteria:

* Patients, aged 18 - 85 years
* Physical status according to the American Society of Anesthesiologists (ASA) I or II, which includes patients who are systemically healthy or suffer under mild to moderate, but well controlled systemic diseases.
* Patients having a minimum of 1 dental implant with peri-implantitis.
* The dental implant with peri-implantitis has ≥ 3 threads exposed or pocket probing depth (PPD) ≥ 5mm, with bleeding on probing (BOP) and/or suppuration (pus).
* The implants are in function for at least 6 months
* No uncontrolled systemic disease or condition known to alter bone metabolism, like Osteoporosis, Osteopenia, Hyperparathyroidism, Paget's disease.
* Only rough surface implant will be included in this study

Exclusion Criteria:

* Long-term use of antibiotics \> 2 weeks in the past two months
* No peri-implantitis treatment in the last 2 months
* Patients taking medications known to modify bone metabolism (such as bisphosphonates, corticosteroids, Hormone replacement therapy for menopausal women, Parathyroid hormone, Denosumab, strontium ranelate).
* Pregnant females or those planning to become pregnant.
* Patients with a history of medically diagnosed oral cancer, bisphosphonate usage, Sepsis or those having adverse outcomes to oral procedures in the past, will be excluded
* Mobility of dental implants
* History of alcoholism or drug abuse
* Current smokers or quit smoking less than 6 months
* Diseases of the immune system or any medical condition that may influence the outcome (uncontrolled diabetes (HbA1c \>7)
* Patients with allergies known to affect one or more of the treatment provided in this study
* Polish surface implants
* Implants with trabecular surface

Primary outcomes:
measure: Perio Probing Depth
timeFrame: Change in probing depth from beginning of study to 6 months after intervention
Secondary outcomes:
measure: Bleeding on Probing
timeFrame: Change in bleeding on probing from beginning of study to 6 months after intervention
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan School of Dentistry
state: Michigan
Study officials:
affiliation: University of Michigan
name: Fernando Suarez, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03278899: A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
Official title: A Non-interventional Study to Prospectively Assess Baseline Status and Disease Progression in Male Children With X-Linked Adrenoleukodystrophy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: X-Linked Adrenoleukodystrophy
Keywords: Adrenoleukodystropy
X-ALD
ALD
Lead sponsor: NeuroVia, Inc.
Sponsor class: INDUSTRY
First posted: 2017-09-12
Enrollment: 100
Sex: MALE
Minimum age (years): 2
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients will be selected from participating sites, referring physicians, and outreach communities

Brief summary: This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice. No study drug treatment will be given and no changes to patient treatment are necessary.

Detailed description: This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice. No study drug treatment will be given and no changes to the patient treatment are necessary.

Patients with X-ALD will be recruited and invited to attend a baseline visit. After eligible patients are enrolled, retrospective and baseline data will be collected. After enrollment, patients will be seen approximately every 6 months until they meet withdrawal criteria or the Sponsor terminates the study.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent by patient's parent(s)/legally acceptable representative(s). In addition, signed children's assent form according to local requirements.
* Males patients 2-13 years of age with a confirmed diagnosis of X-ALD that fall into one of the following:

  * Asymptomatic patients without MRI evidence of cerebral involvement
  * Patients with MRI evidence of cerebral involvement (Loes score ≥0.5) with or without clinical symptoms
  * Patient who have HSCT within 3 months from enrollment

Exclusion Criteria:

* Patients who are 14 years of age or older
* Patients who are in a vegetative state
* Patients (or their guardians) who are unwilling or unable to comply with the study procedures
* Patients who received HSCT more than 3 months before enrollment

Primary outcomes:
measure: Loes score
timeFrame: baseline and 24 weeks
measure: Plasma VLCFA levels
timeFrame: baseline and 24 weeks
measure: Neurological symptoms
timeFrame: baseline and 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: NeuroVia, Inc.
name: John Henderson, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00823199: An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
Official title: An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Lead sponsor: Bronx Psychiatric Center
Sponsor class: OTHER_GOV
First posted: 2009-01-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.


Eligibility criteria: Inclusion Criteria:

* Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion Criteria:

* Over 65
* Renal or liver disease
* Diabetes
* Hypertension
* Taking thiazides or ACE inhibitors

Primary outcomes:
measure: Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia
timeFrame: baseline and 4 weeks
Secondary outcomes:
measure: Simpson Angus Scale for Parkinsonism
timeFrame: baseline and 4 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Bronx Psychiatric Center
name: Nigel Bark, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04421599: Necessity of Aspiration in the Ventrogluteal Site
Official title: Investigation of the Necessity of Aspiration During The Intramuscular Injection Administered in the Ventrogluteal Site and Its Effect on Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Nursing
Injection Site
Keywords: Ventrogluteal area
aspiration
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2020-06-09
Enrollment: 834
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: H1: Aspiration is not necessary for IM injections applied from the ventrogluteal region.

H2: Aspiration procedure increases pain in IM injections applied from ventrogluteal region.

H3: The duration of the aspiration procedure on IM injections applied from the ventrogluteal region is effective on pain.


Eligibility criteria: Inclusion Criteria:

* Patient who came to the Emergency Service Care Unit for "Diclofenac Sodium" injection
* Have no vision and hearing problems,
* Who have no disease that may affect their perception of pain
* Who can evaluate the "Visual Analog Scale" correctly, scoring 5 points or less from the VAS,
* Body Mass Index is between 18.5-24.9 kg / m2,
* Who do not have any discomfort in the extremities that will prevent them from taking the desired position,
* No complications due to intramuscular injections such as abscess, infection, tissue necrosis and hematoma in the ventrogluteal region
* No nodules or masses in the area

Exclusion Criteria:

* Patients who refuse the injection are excluded.

Primary outcomes:
measure: Individual Introductory Information Form
timeFrame: 15 minutes
measure: Visual Analog Scale (VAS)
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: Ege University Hospital
Study officials:
References:
citation: Beyea SC, Nicoll LH. Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res. 1995 Feb;8(1):23-33. doi: 10.1016/s0897-1897(95)80279-7.
Clinical trial NCT01269099: Hypokalemia and Intravenous Patient Controlled Analgesia
Official title: Hypokalemia and Intravenous Patient Controlled Analgesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Laparoscopic Cholecystectomy
Keywords: hypokalemia
intravenous patient controlled analgesia
Lead sponsor: Seoul Medical Center
Sponsor class: OTHER
First posted: 2011-01-04
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The increase in stress hormone level and hyperventilation caused by the postoperative pain may contribute to the development of hypokalemia during postoperative period. Therefore, if the postoperative pain is well controlled by the IV-PCA,the plasma potassium level during the postoperative period may be not affected by stress response. The researchers tried to investigate the effect of IV-PCA on potassium regulation during the postoperative period.

Detailed description: Intravenous patient controlled analgesia(IV-PCA) has been widely used to control postoperative pain. The increase in stress hormone level and hyperventilation caused by the postoperative pain may contribute to the development of hypokalemia during postoperative period. Hypokalemia is a risk factor for postoperative arrhythmia. Therefore, if the postoperative pain is well controlled by the IV-PCA, the plasma potassium level during the postoperative period may be not affected by stress response, and the incidence of hypokalemia may be reduced. The researchers tried to investigate the effect of IV-PCA on potassium regulation during the postoperative period.

The researchers divided the patients undergoing laparoscopic cholecystectomy into two groups of IV-PCA group and control group. The researchers compared the plasma potassium concentration from the preoperative to postoperative period.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing laparoscopic cholecystectomy
* ASA class I or II

Exclusion Criteria:

* Any patients with plasma aldosterone, or glucocorticoid disorder including primary hyperaldosteronism, renovascular hypertension, rennin-secreting tumor, salt-wasting renal disease, Cushing syndrome
* Patients with recent exogenous steroid administration or previous diuretics therapy

Primary outcomes:
measure: plasma potassium concentration
timeFrame: one day interval (average)
Secondary outcomes:
measure: Visual Analogue Scale (VAS) score
timeFrame: one day interval (average)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul Medical Center
Study officials:
affiliation: Seoul Medical Center
name: Won Ho Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05058599: Reconstruction Technology to Auxiliary Diagnosis and Guarantee Patient Privacy
Official title: Using a Reconstruction Technology With Facial Pathological Features to Auxiliary Diagnosis and Guarantee Patient Privacy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: 3D-reconstruction
Patient Privacy
Deep Learning
Digital Medicine
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients from strabismus departments, paediatric ophthalmology departments, TAO departments, and ophthalmic plastic departments.

Brief summary: Medical data that contain facial images are particularly sensitive as they retain important personal biometric identity, privacy protection. We developed a novel technology called "Digital Mask" (DM), based on real-time three-dimensional (3D) reconstruction and deep learning algorithm, to extract disease-relevant features but remove patient identifiable features from facial images of patients.


Eligibility criteria: Inclusion Criteria:

* The quality of facial images should be clinically acceptable.

Primary outcomes:
measure: Diagnostic consistency
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center
state: Guangdong
Study officials:
References:
Clinical trial NCT02582099: The Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis
Official title: Comparison of the Efficacy and Complication of Gentamicin and Normal Saline Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis : a Double Blind Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Rhinosinusitis
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2015-10-21
Enrollment: 40
Sex: ALL
Minimum age (years): 7
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Topical antibiotic therapy in patients with refractory sinusitis has been shown to improve symptoms, quality of life, and mucosal aspect. In pediatrics allergy clinic at Siriraj hospital since 2006 use Gentamicin nasal irrigation for chronic rhinosinusitis.There have been no prospective studies in gentamicin irrigation in chronic rhinosinusitis.

Detailed description: Chronic rhinosinusitis (CRS) is characterized by symptoms \> 12 weeks.Two or more symptoms one of which should be either nasal blockage /obstruction/congestion or nasal discharge (anterior/posterior nasal drip): facial pain/pressure reduction or loss of smell).

Mainstay of treatment are medical and surgical treatment ( ATB, adenoidectomy, ESS) Adjunctive treatment : normal saline nasal irrigation, nasal corticosteroids, nasal decongestants, mucolytics. Nasal lavage with Mupirocin represent an effective and well tolerated alternative treatment of surgically recalcitrant chronic rhinosinusitis. Gentamicin irrigation should be helpful in chronic rhinosinusitis.

Eligibility criteria: Inclusion Criteria:

1. Chronic rhinosinusitis and/or recurrent acute/subacute sinusitis patients who were followed in pediatrics allergy clinic at Siriraj hospital between December 4, 2012, and December 3, 2016

Exclusion Criteria:

1. Patients who used antibiotic prophylaxis within within 1 year before and 6 months after started gentamicin nasal irrigation
2. Patients received IVIG within 1 year before and 6 months after started gentamicin nasal irrigation
3. Patients received IT within 1 year before and 6 months after started gentamicin nasal irrigation
4. Patients underwent endoscopic sinus surgery within 1 year before and 6 months after started gentamicin nasal irrigation
5. Patient who have mental retardation
6. Patient who have aminoglycosides hypersensitivity reactions
7. Pregnancy women and Lactation period
8. Patient who have abnormal hearing test before started gentamicin nasal irrigation
9. Patient who have chronic rhinosinusitis with nasal polyp

Primary outcomes:
measure: Frequency of sinusitis
timeFrame: During 1 year after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Faculty of Medicine Siriraj Hospital
state: Bangkok
Study officials:
References: